Ligand-directed strategies are conceptually attractive but require careful risk assessment: anti-NGF monoclonal antibodies demonstrate on-mechanism analgesia yet carry joint-specific toxicities that are relevant to sarcoma populations with musculoskeletal comorbidities (92–94). Here, NGF is linked to sarcoma.